Ingredion (CNP) AI Stock Analysis

Company Guidance

Ingredion reaffirmed full-year 2026 guidance with adjusted EPS of $10.30–$10.90 (assuming diluted shares of 63–64 million and completion of $100 million of share repurchases), net sales expected flat to up low single digits, and adjusted operating income down mid-single digits (amended to reflect the sale of the majority stake in Pakistan). Full-year cash from operations is now forecast at $700–$800 million and capital expenditures $450–$490 million (including additional Argo spend); Q3 is expected to see net sales up low single digits and adjusted operating income down mid-single digits with higher sequential corporate costs. By segment, Texture & Healthful Solutions is expected to deliver net sales up mid-single digits and operating income up mid‑ to high‑single digits (T&HS Q2 net sales +5%, volumes +7%), Food & Industrial Ingredients LATAM net sales up low single digits with operating income down low single digits, Food & Industrial Ingredients U.S./Canada net sales down low single digits with operating income down 20%–25%, and All Other net sales down 20%–25% with an operating loss of about $15 million. For context, Q2 reported net sales were $1.85 billion (+1%), adjusted operating income $258 million (‑5% YoY), year‑to‑date net sales ≈ $3.6 billion (flat), and YTD adjusted operating income $470 million (‑14%); the company also noted transaction metrics for the pending Tate & Lyle deal of $2.7 billion of revenue addition, $130 million run‑rate synergies by 2030, >15% adjusted EPS accretion in the first full year post‑close and a path to <2.5x net leverage within 18 months. Guidance assumes current tariff levels as of end‑July 2026 and excludes acquisition integration/restructuring and potential impairments.